Doctor’s Passport

Find your next topic

Explore the current textbook

CardiologyRespiratoryNeurology
Available drafts · Clinical review pending
Membership
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Textbook/Neurosurgery/Anticoagulant reversal in intracranial bleeding
Full textbook

Anticoagulant reversal in intracranial bleeding

Initiate drug-specific haemostatic treatment for life-threatening intracranial bleeding while preserving urgent neurological care, recognising UK authorisation and access boundaries, and planning monitored anticoagulation restart.

26 min full readUK scopeSources checked 13 Sept 2026Clinical review pending
Saved on this device
!
Reverse in parallel with brain rescue

Anticoagulant-associated intracranial haemorrhage can expand quickly; reversal must begin from the exact agent and exposure while airway, blood pressure, CT, critical care and neurosurgical decisions continue.

Action: Stop the anticoagulant, establish the drug, dose and last administration, send urgent haemostasis and renal tests, contact haematology/pharmacy and give the current locally authorised agent-specific reversal without waiting for deterioration or routine laboratory normalisation.

Open the sections you need. The overview is shown first.
01Principles and purposeThe professional or clinical skill and the decisions it supports.

Reversal aims to remove a modifiable driver of haematoma expansion quickly enough to preserve brain tissue and allow surgery or drainage. It does not replace airway management, blood-pressure control, repeat CT, treatment of raised intracranial pressure or evacuation decisions. The first high-value act is accurate medication reconciliation: generic terms such as 'blood thinner' conceal mechanisms, half-lives, assays and antidotes that differ substantially.

Vitamin K antagonists suppress synthesis of factors II, VII, IX and X. Four-factor PCC replaces them immediately, while intravenous vitamin K enables sustained endogenous production; PCC without vitamin K can wear off. Dabigatran directly inhibits thrombin and is specifically bound by idarucizumab. Apixaban and rivaroxaban inhibit factor Xa. Andexanet acts as a decoy Xa protein, but BSH 2026 warns that its increased thrombotic risk, particularly ischaemic stroke, may outweigh benefit. UK licensing nevertheless continues for adult life-threatening or uncontrolled apixaban- or rivaroxaban bleeding. NHS Scotland has interim any-site acceptance, while NICE TA697 recommends only qualifying gastrointestinal bleeding and TA1029 made no intracranial recommendation after the company declined an evidence submission; local rational decision-making remains possible.

Unfractionated heparin has a short half-life and can be neutralised by protamine; low-molecular-weight heparin reversal is incomplete and depends on timing. Antiplatelet drugs impair platelet function rather than coagulation factors and need a separate indication-specific plan. In all groups, haemostatic benefit must be balanced later against venous or arterial thrombosis, mechanical valves, atrial fibrillation and recent thromboembolism. That balance belongs after immediate bleeding control and serial confirmation of stability.

Key points

  • Treat anticoagulant-associated intracranial haemorrhage as simultaneous neurological and haemostatic emergencies: stop exposure, stabilise, image, reverse and seek specialist source control.
  • Identify the exact medicine, indication, dose, last administration, renal function, weight and interacting drugs; warfarin, dabigatran, factor Xa inhibitors and heparins are not interchangeable.
  • Match reversal to mechanism: PCC plus intravenous vitamin K for VKA; idarucizumab for dabigatran; selective UK-policy-directed andexanet or off-label PCC assessment for apixaban/rivaroxaban; protamine for recent heparin exposure.
  • Idarucizumab is the specific reversal agent for clinically significant dabigatran effect; coagulation testing and renal function help detect persistent or recurrent activity.
  • For apixaban or rivaroxaban, follow the current UK-nation and local pathway: BSH advises selective risk–benefit assessment, andexanet authorisation does not equal uniform NHS access, and four-factor PCC is an off-label specialist option.
  • Protamine reverses unfractionated heparin more completely than low-molecular-weight heparin; calculate from recent exposure and monitor because excess protamine is itself harmful.
  • Repeat neurological examination and CT as indicated, verify haemostatic response with drug-appropriate tests, prevent thrombosis safely and make a multidisciplinary restart decision based on bleed stability and the original indication.
02Situations and prioritiesThe context, relevant information and actions that matter most.
Clinically significant exposure

Recent ingestion, impaired renal clearance, overdose, interacting medicines or a prolonged drug-specific assay increases the likelihood that anticoagulant effect is contributing to bleeding.

Expanding haemorrhageRed flag

Worsening deficit, consciousness or pupils and increased blood on repeat imaging indicate failed control and demand escalation of both haemostatic and neurosurgical treatment.

Occult residual effect

A normal routine coagulation screen may coexist with a clinically important direct Xa inhibitor concentration; use drug history and calibrated testing where rapidly available.

Reversal complicationRed flag

Chest pain, limb ischaemia, hypoxaemia, new focal deficit or circuit thrombosis after reversal raises concern for arterial or venous thromboembolism and needs urgent assessment.

Rebound anticoagulation

Persistent absorption, redistribution or renal failure can produce renewed anticoagulant activity after initial improvement, particularly when drug clearance remains impaired.

Red flags requiring action

  • Falling consciousness, worsening focal deficit, new anisocoria or haematoma expansion requires immediate neurocritical and neurosurgical action even while reversal is being prepared.
  • The phrase 'DOAC' is insufficient: dabigatran and factor Xa inhibitors use different assays and specific antidotes, and renal clearance changes the likely residual effect.
  • Routine coagulation tests do not provide a universal measure for every direct oral anticoagulant; interpret testing from the identified drug, timing, renal function and a validated drug-specific assay where available.
  • Andexanet retains UK marketing authorisation for adults with life-threatening or uncontrolled apixaban- or rivaroxaban-associated bleeding, but BSH 2026 warns that increased thrombosis, particularly ischaemic stroke, may outweigh benefit and NHS access differs by jurisdiction.
  • Every reversal agent carries thrombosis or rebound-anticoagulation concerns; these require monitoring and a later restart plan, not delay of haemostasis in active intracranial bleeding.
  • Antiplatelet exposure is a separate problem and routine platelet transfusion is not a generic substitute for anticoagulant reversal.
03Assessment and interpretationHow to gather information, assess the situation and recognise uncertainty.
Reasoning sequence

Consider the information, its meaning and its limitations before deciding what follows.

  1. 01
    Immediate non-contrast CT head
    Why
    Define site, volume, mass effect, intraventricular extension and surgical urgency before and during reversal.
    Interpretation and limitations
    Expansion or new hydrocephalus changes neurological treatment; a stable initial scan does not exclude later growth during residual anticoagulant effect.
  2. 02
    Full blood count, PT/INR, APTT, fibrinogen and group-and-save
    Why
    Identify anaemia, thrombocytopenia, VKA effect and additional coagulopathy while preparing haemostatic support.
    Interpretation and limitations
    INR guides VKA reversal; a routine PT or APTT is not a universal quantitative assay for all direct oral anticoagulants and must be interpreted with the exact agent and exposure.
  3. 03
    Thrombin time or dabigatran-calibrated assay
    Why
    Assess whether clinically relevant direct thrombin-inhibitor activity may persist or recur.
    Interpretation and limitations
    A normal thrombin time usually argues against significant dabigatran effect, whereas abnormal or calibrated results require timing and renal-context interpretation.
  4. 04
    Drug-calibrated anti-Xa level
    Why
    Estimate apixaban or rivaroxaban activity when a rapid validated assay is available and will not delay treatment.
    Interpretation and limitations
    A drug-specific low level may avoid unnecessary antidote exposure; an uncalibrated heparin assay or normal PT cannot provide the same assurance.
  5. 05
    Urea, creatinine and estimated renal function
    Why
    Estimate drug clearance and risk of prolonged or recurrent direct-anticoagulant effect.
    Interpretation and limitations
    Renal failure particularly prolongs dabigatran and can change the expected activity of other agents, repeat testing and specialist options.
  6. 06
    Repeat CT and haemostasis testing
    Why
    Determine whether reversal has stabilised the bleed and corrected the relevant anticoagulant effect.
    Interpretation and limitations
    Clinical decline or radiological growth overrides a reassuring single laboratory value and prompts renewed multidisciplinary review.
04Worked approachesCases with ordered reasoning, an action and a check of the outcome.
01Worked case: emergency reversalReverse the identified anticoagulantAcute intracranial haemorrhage is confirmed or strongly suspected in a person with potentially active anticoagulant exposure.
  1. 1Stop further anticoagulant and activate stroke, neurosurgical, critical-care, haematology, transfusion and pharmacy support while securing airway, circulation, blood pressure and immediate CT.
  2. 2Establish the exact medicine, dose, last administration, indication, renal function, weight and interacting drugs; send INR, APTT, fibrinogen, blood count, renal tests and drug-specific assays when rapidly available without delaying indicated reversal.
  3. 3For warfarin give urgent four-factor PCC plus intravenous vitamin K according to presenting INR and the current authorised protocol; for dabigatran use idarucizumab when clinically relevant activity is likely.
  4. 4For apixaban or rivaroxaban apply the current nation-specific and local specialist pathway, weighing BSH's 2026 thrombotic warning; if andexanet is considered, verify eligibility and do not derive a dose when the last dose amount or timing is unknown, because the UK SmPC provides none.
  5. 5For recent unfractionated or low-molecular-weight heparin calculate protamine from agent, dose and elapsed time, recognising incomplete LMWH neutralisation; manage antiplatelet exposure through its separate evidence-based pathway.
  6. 6Reassess examination, imaging and drug-appropriate haemostasis after treatment, escalate expansion or herniation, monitor for thrombosis and document an interim thromboprophylaxis and anticoagulation-restart plan.
02Uncertain-drug pathwayUnknown blood thinnerIntracranial bleeding is present but the exact antithrombotic cannot yet be confirmed.
  1. 1Search the medication record, dispensing history, electronic summary, tablets, family account and recent procedure notes while emergency brain care continues.
  2. 2Use INR, thrombin time, calibrated assays, renal function and last-known exposure to narrow the mechanism; call haematology and pharmacy early.
  3. 3Do not give a mechanism-specific antidote merely because it is stocked; choose treatment from the best verified exposure and the risk of delaying haemostasis.
03Restart pathwayAfter haemorrhage stabilisationClinical and radiological haemostasis has been achieved and the thrombosis indication must be reconsidered.
  1. 1Reassess bleed cause, location, size, treatment, stability and recurrence risk alongside mechanical valve, embolic, venous-thromboembolism and mobility risks.
  2. 2Use mechanical thromboprophylaxis and introduce pharmacological prophylaxis only when the lesion-specific team considers haemostasis secure.
  3. 3Make and document a multidisciplinary drug, dose and timing decision; do not allow temporary reversal to become an accidental permanent omission or automatic early restart.
05Relevant medicines and safetySpecific regimens and precautions when the skill involves prescribing.
PCC replaces vitamin-K-dependent factors rapidly while vitamin K restores endogenous synthesis after warfarin-associated life-threatening intracranial bleeding.

Four-factor prothrombin complex concentrate plus intravenous phytomenadione

Use the current UK product and local major-haemorrhage protocol, calculating PCC from presenting INR and weight and giving intravenous vitamin K concurrently for sustained VKA reversal.

Verify INR response, avoid unnecessary repeat PCC, watch for thrombosis and volume issues, and remember that vitamin K alone is too slow for immediate haemostasis.

Specifically binds dabigatran to permit rapid haemostatic control and urgent intervention.

Idarucizumab

For adult emergency reversal of clinically relevant dabigatran effect, give 5 g intravenously as two consecutive 2.5 g/50 mL vials, each over 5–10 minutes or as a bolus, using current product information.

It does not reverse factor Xa inhibitors or warfarin; reassess bleeding and coagulation for recurrent activity, particularly with renal failure, and reserve a second 5 g dose for the SmPC's conditional recurrent-activity situations.

Decoy factor Xa protein authorised in the UK for adults requiring reversal of apixaban or rivaroxaban because of life-threatening or uncontrolled bleeding.

Andexanet alfa

Use only through the current UK-nation and local specialist pathway and current SmPC drug, dose and timing table; there is no UK dose recommendation when either the last anticoagulant amount or interval is unknown.

BSH 2026 warns that thrombotic and stroke risk may outweigh benefit; it is not licensed for edoxaban, heparins or reversal solely before urgent surgery, commercial anti-Xa assays are unreliable after use, and heparin resistance can occur.

Neutralises circulating heparin and partially reverses low-molecular-weight heparin anticoagulant activity.

Protamine sulfate

Calculate from the heparin type, amount and elapsed time using the current product and local protocol; recent unfractionated heparin is more completely neutralised than low-molecular-weight heparin.

Rapid or excessive administration can cause hypotension, bradycardia, pulmonary vasoconstriction and anticoagulant effects; LMWH reversal is incomplete and needs specialist follow-up.

06Feedback, follow-up and evidenceReview outcomes, seek feedback and identify what to improve.
  • Repeat pupils, consciousness, motor findings and vital physiology through treatment and arrange interval CT according to haemorrhage type, trajectory and any deterioration.
  • Recheck INR soon after PCC for VKA exposure and use agent-appropriate assays for dabigatran or Xa inhibitors when results can guide persistent or recurrent effect.
  • Track haemoglobin, platelet count, fibrinogen, renal function and all bleeding sites, especially when trauma, surgery, liver disease or massive transfusion adds another coagulopathy.
  • Observe for arterial and venous thrombosis after reversal, including stroke, myocardial infarction, pulmonary embolism and limb ischaemia, without allowing surveillance to postpone initial haemostasis.
  • Document the original anticoagulation indication and a dated senior plan for mechanical prophylaxis, pharmacological prophylaxis and therapeutic restart or permanent change.
07Special situationsVariants, exceptions and circumstances that change the usual approach.

History is a haemostasis test

The named drug, time, dose and renal clearance may be more actionable than a normal generic PT or APTT for direct oral anticoagulant exposure.

Two speeds for warfarin

PCC supplies factors immediately, whereas intravenous vitamin K sustains correction; using only one leaves either delay or rebound anticoagulation.

Authorisation differs from access

A UK marketing authorisation defines the licensed indication, while NICE or Scottish reimbursement and local commissioning determine whether intracranial use is available in a given service.

Reversal has an endpoint

The goal is clinical and radiological haemostasis with corrected relevant anticoagulant effect, not indiscriminate normalisation of every coagulation result.

Restart is active treatment

Both premature resumption and indefinite omission can cause harm, so the decision needs lesion stability, indication strength and a documented review date.

08Common pitfallsFrequent interpretation and management errors.
  1. 01

    Choosing an antidote from the word DOAC without identifying whether the patient takes dabigatran, apixaban, rivaroxaban or another agent.

  2. 02

    Waiting for a normal or abnormal routine coagulation screen before treating a convincing life-threatening exposure.

  3. 03

    Giving vitamin K without rapid factor replacement for severe warfarin-related intracranial haemorrhage.

  4. 04

    Assuming UK marketing authorisation means andexanet is commissioned for intracranial bleeding in every UK nation and hospital.

  5. 05

    Reversing the drug but failing to continue serial neurology, repeat imaging, raised-pressure care and neurosurgical source-control decisions.

  6. 06

    Failing to revisit thromboprophylaxis and therapeutic anticoagulation after haemostasis, creating preventable thromboembolism.

Practice

Two practice questions

Question 1 of 20 correct
NeurosurgeryOriginal SBA

Warfarin-associated intracranial bleeding

An adult taking warfarin presents with acute intracerebral haemorrhage and an elevated INR. Which immediate reversal principle is most appropriate while neurosurgical and stroke care proceed?

Sources and review status8 sources · checked 13 Sept 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 13 Sept 2026; clinical approval remains outstanding.

  • BSH guideline on bleeding in patients on antithrombotic agentsUK professional guidance dated 1 November 2012 with BSH review recorded 2 June 2019; Table 1 and UFH/LMWH and VKA sections read 13 September 2026. Used only for established VKA and heparin principles; historical statements predating specific DOAC antidotes are superseded.
  • BSH 2026 position statement on andexanet alfaFull UK professional position body published 25 April 2026, recommendations read 13 September 2026. Warns that increased thrombosis, particularly ischaemic stroke, may outweigh benefit; it does not revoke the UK licence or decide local commissioning.
  • NICE TA697 andexanet alfa recommendationsTechnology appraisal recommendations published 12 May 2021 and checked 13 September 2026. Recommends andexanet only for reversing apixaban or rivaroxaban in adults with life-threatening or uncontrolled gastrointestinal bleeding; it does not recommend NHS use for intracranial haemorrhage in its jurisdiction.
  • NICE TA1029 terminated intracranial andexanet appraisalTerminated appraisal status checked 13 September 2026. The absence of a NICE intracranial recommendation is recorded as a commissioning boundary, not misrepresented as cancellation of UK marketing authorisation or a universal prohibition.
  • Praxbind UK summary of product characteristicsUK SmPC updated 17 January 2025; sections 4.1–4.4 read 13 September 2026 for the adult dabigatran emergency indication, 5 g administration, recurrent-activity provision and monitoring. It does not establish lesion-specific anticoagulation restart timing.
  • Ondexxya UK summary of product characteristicsUK SmPC updated 5 March 2026; sections 4.1–4.4 and ANNEXA-I population read 13 September 2026. Adult apixaban/rivaroxaban licence only; no dose recommendation if last amount or interval is unknown, anti-Xa assay and heparin-resistance cautions; commissioning and stock are separate.
  • National Clinical Guideline for Stroke: acute careUK and Ireland stroke guideline 2023, recommendations 3.6A–B and evidence-to-recommendation text read 13 September 2026. Supports VKA and dabigatran reversal in acute spontaneous ICH; its older andexanet trial-only wording is superseded by current BSH and product information.
  • ESO–EANS guideline on spontaneous intracerebral haemorrhageEuropean adult spontaneous-ICH guideline published 22 May 2025; oral anticoagulant reversal recommendations read 13 September 2026. Used for uncertain PCC and andexanet net benefit and antiplatelet separation; it does not cover trauma, paediatric bleeding or UK access.
Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom